Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chen's Tangshen Formula (陈氏糖肾方) is a proprietary traditional Chinese medicine (TCM) compound formula developed for the treatment of diabetic kidney disease (DKD), also known as diabetic nephropathy. The formula is based on TCM principles, with reported effects of "tonifying qi and nourishing yin, activating blood circulation, and resolving stasis." Clinical studies indicate that it can improve renal function in patients with DKD, particularly when initiated in early stages of the disease[3][9]. Mechanistic research suggests that its pharmacological actions include anti-inflammatory effects, antioxidative stress reduction, inhibition of fibrosis and lipid deposition in the kidney, and suppression of pyroptosis via modulation of the TXNIP-NLRP3-GSDMD axis. This results in reduced proteinuria and improved renal pathology[5]. The formula is used orally as a decoction or granule preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chen's Tangshen Formula.